Zacks upgrades Bristol Myers Squibb stock to Strong Buy

Published on 10/05/2026 at 13:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zacks raised fiscal 2027 earnings per share to USD 6.24 from USD 6.23. Bristol Myers Squibb stock costs EUR 54.50 on October 5, 2026 after EUR 54.42.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) stock is trading at EUR 54.50 at Lang & Schwarz on October 5, 2026, up 0.15 percent from the EUR 54.42 prior close. The latest analyst signal came on September 25, 2026, when MarketBeat reported that Zacks Research upgraded the company from Hold to Strong Buy and raised its fiscal 2027 earnings-per-share estimate from USD 6.23 to USD 6.24.

Strong Buy meets earnings growth

The upgrade follows a second-quarter 2026 performance that gave the rating a concrete operating backdrop. Bristol Myers Squibb reported USD 12.97 billion in revenue and USD 2.04 in earnings per share, compared with consensus revenue of USD 11.74 billion and consensus earnings per share of USD 1.60, according to MarketBeat. Revenue was 5.70 percent higher than in the same quarter of 2025, while earnings per share exceeded consensus by USD 0.44.

The company also maintained fiscal 2026 earnings-per-share guidance of USD 6.75-7.00, a range cited by MarketBeat. That outlook places the newer pipeline assets alongside mature medicines as the key test for the company's earnings profile.

Pipeline targets support valuation

Piper Sandler raised its price target for Bristol Myers Squibb from USD 75.00 to USD 82.00 on September 16, 2026, while maintaining an Overweight rating, as Investing.com reported. The analyst cited upcoming milestones for milvexian, Cobenfy and admilparant, while also pointing to patent expirations and pressure on established blockbuster products as counterweights.

Income remains part of the investor case. Bristol Myers Squibb declared a quarterly dividend of USD 0.63 per share on September 16, 2026, payable November 2, 2026, to shareholders of record on October 2, 2026, according to the company's Bristol Myers Squibb release.

Stock remains below its yearly high

The NYSE-listed stock's primary-market quote was USD 61.15 on October 2, 2026 at 4:00 p.m. ET. Its 52-week range was USD 42.52 to USD 68.64, and its market capitalization was USD 124.9 billion as of October 2, 2026.

The Lang & Schwarz quote was EUR 54.50 in trading on October 5, 2026 at 1:16 p.m. CEST, plus 0.15 percent versus the prior close of EUR 54.42. The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.